Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by OKYO Pharma LTD

< Previous 1 2 Next >
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Limited Announces Withdrawal of Public Offering
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 2023
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Limited Announces Withdrawal of Public Offering
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
Notice of General Meeting and Publication of Circular
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
Notice of Intention to Delist From The London Stock Exchange
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Today Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces PDMR Dealing
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.